Gothenburg, 2013-06-18 10:50 CEST (GLOBE NEWSWIRE) — Immunicum AB (publ), a Swedish listed company developing therapeutic cancer vaccines, today received prolonged SME-status from the European Medicines Agency. The status is extended one year with the possibility of further extension and means significantly lower fees and faster handling on cases involving EMA. The purpose of EMA’s SME department is to actively promote the innovation and development of drugs in small and medium size enterprises.
Immunicums patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body’s own immune system to attack harmful substances like tumor cells. In February 2012, Immunicum initiated its first clinical phase I/II-study in metastatic renal cancer where today 10 out of 12 patients have been treated, so far with promising results. During the summer, a decision from the Swedish Medical Products Agency is expected concerning an application to start another phase I/II-study in primary liver cancer.
Immunicum’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body’s own immune system to attack harmful substances like tumor cells. Immunicum’s shares have been traded since April 22, 2013 at NASDAQ OMX First North under the ticker IMMU.
G&W Fondkommission is chosen as the Company’s Certified Adviser.
Tel: +468-503 000 50. www.gwkapital.se.
For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,
About Immunicum AB (publ):
Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX(TM) and INTUVAX(TM), and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum’s products can be produced in large scale. The vaccines have earlier proven efficacy in animal studies and are now undergoing clinical trials in patients.